VistaGen Therapeutics (VTGN) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
13 Nov, 2026Executive summary
Q2 net loss narrowed YoY to $10.7M from $19.4M; six-month net loss was $23.8M vs. $34.5M. Cash, cash equivalents and marketable securities totaled $20.0M at Sept. 30, 2026.
Substantial doubt exists about the ability to continue as a going concern; available resources are expected to fund operations into 2027, but not for at least 12 months from the report date.
FDA feedback clarified potential fasedienol Phase 3 pathways, with planned development aimed at treating overall SAD in the general population, subject to funding.
Financial highlights
Q2 revenue was $138K vs. $258K YoY; six-month revenue was $1.614M vs. $502K, including $1.3M recognized after the Fuji Pharma negotiation period ended.
Q2 operating expenses were $11.1M vs. $20.3M YoY, including R&D expense of $6.6M vs. $15.9M; six-month expenses were $25.9M vs. $36.4M, mainly reflecting lower R&D spending.
Q2 operating loss was $10.9M vs. $20.1M YoY; six-month operating loss was $24.3M vs. $35.9M. Loss per share was $0.24 and $0.54, respectively, vs. $0.54 and $1.02.
Q2 G&A expense was $4.5M vs. $4.4M YoY.
Six-month operating cash use was $26.9M vs. $32.6M; cash and cash equivalents declined to $10.9M from $30.8M at March 31, 2026.
Outlook and guidance
Remaining AffaMed deferred revenue of $0.1M is expected to be recognized during the rest of FY2027; absent milestones or similar deals, future sublicense revenue is expected to be substantially lower than the current six-month amount.
Phase 3 planning will incorporate FDA recommendations, including LSAS as the primary endpoint and interim eDiary and patient-survey assessments; FDA feedback does not assure a registrational pathway.
R&D expense is expected to decline further after the October workforce reduction, partly offset by ~$1.0M in severance costs in the December 2026 quarter; future spending depends on funding a new fasedienol Phase 3 trial.
The October workforce reduction is expected to lower annual salary and benefit costs by ~$3.2M; existing resources are insufficient for another fasedienol Phase 3 trial or further pherine development.
Latest events from VistaGen Therapeutics
- All agenda items, including director elections and auditor ratification, were approved.VTGN
AGM 2026 - Net loss narrowed, cash runway into 2027, but going concern risk persists.VTGN
Q1 2027 - Board seeks approval for director elections, executive pay, and auditor ratification, emphasizing governance and ESG.VTGN
Proxy filing - Shareholders will vote virtually on directors, executive pay, and auditor ratification in 2026.VTGN
Proxy filing - Late-stage intranasal drugs show rapid, safe effects for anxiety, depression, and hot flashes.VTGN
TD Cowen 45th Annual Health Care Conference - Pivotal trials for novel neurocircuitry therapies advance, with key data expected next year.VTGN
Stifel 2024 Healthcare Conference - Net loss rose as R&D spending increased for late-stage trials; cash runway exceeds 12 months.VTGN
Q2 2025 - Net loss rose to $10.7M as R&D spending increased; $108.4M in cash supports ongoing trials.VTGN
Q1 2025 - Phase 3 SAD trials advance, net loss widens, R&D up, cash at $88.6M supports pipeline.VTGN
Q3 2025